For the first time in 15 years! Tumor electro-field therapy has been approved for the treatment of glioblastoma.

On the evening of May 13, Reding Pharmaceuticals announced that China's State Drug Administration had approved the application for the application of the tumor electric field for the treatment of Epden for the treatment of newly diagnosed glioblastoma patients in conjunction with dimoamines, as well as for patients with recurrent glioma as a single therapy.
means the treatment becomes the first treatment in 15 years Chinese mainland approved for glioblastoma.
glioblastoma is the most common and invasive adult brain tumor, accounting for 56% of all gliomas and 15% of all primary brain tumors. As the most common malignant tumor of the nervous system, glioma is highly malignant, fast growth, short course, prone to recurrence after surgery and high lying disability, is considered to be one of the most difficult refractive tumors in neurosurgery treatment. The five-year survival rate of glioblastoma is only 1/3 of lung cancer. In glioma, glioblastoma has the highest degree of malignancy, the patient's five-year survival rate is less than 5%, the prognosis is very poor.
tumor electric field therapy is an innovative treatment for glioblastoma by transmitting a specific electric field to a specific tumor region, which interferes with the filamentofing of tumor cells. To date, more than 15,000 glioblastoma patients have been treated worldwide."In China, more than 45,000 patients are diagnosed with glioblastoma each year, and treatment is very limited," said Professor Jiang Tao of Beijing Institute of Neurosurgery, director of the Beijing Institute of Neurosurgery, founder and founder of the China Glima Genome Atlas Database and founder of The Tiantan Hospital in Beijing.
As the first new treatment in the field in more than a decade, EppDun has been included as a level 1 evidence in the Health AndI's first "Guidelines for the Diagnosis and Treatment of Gliomas( 2018 Edition)." We look forward to it as a standard treatment for patients with glioblastoma, offering hope to more patients.
it is understood that Reding Pharmaceuticals has been granted exclusive authorization by Novocure to develop and market the treatment of cancer electric fields in Greater China. In addition, tumor electro-field treatment has been approved by the U.S. Food and Drug Administration through a humanitarian equipment waiver for the treatment of malignant pleural mesothelioma, and applications for this indication will subsequently be submitted domestically.
.